Stock RGC REGENCELL BIOSCIENCE HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Regencell Bioscience Holdings Limited

Equities

RGC

KYG7487R1002

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
4.67 USD +6.14% Intraday chart for Regencell Bioscience Holdings Limited -0.64% -55.52%
2023 Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
2023 Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022
CI
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2022
CI
Regencell Bioscience Holdings Limited Announces its Standardized Formulae Shows Reduce ADHD and ASD Symptoms in Interim Results of its Second Efficacy Trial
CI
Regencell Bioscience : Announces First Half 2022 Management Financial Results - Form 6-K
PU
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2021
CI
Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period
CI
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
BU
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
BU
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19 Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial
CI
Certain Warrants of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 12-JAN-2022.
CI
Certain Ordinary Shares of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 12-JAN-2022.
CI
Regencell Bioscience : Forms Joint Venture to Offer COVID-19 Treatment to Select Asia Pacific Countries
MT
Update: Regencell Bioscience Raises $24.9 Million from IPO -- Shares More Than Triple Amid Heavy Trading Volume
MT
Regencell Bioscience : Says IPO Raised $24.9 Million
MT
Regencell Bioscience Holdings Limited : Announces Closing of Initial Public Offering
BU
Regencell Bioscience : Hong Kong's Regencell Bioscience Rises in Nasdaq Debut
MT
Regencell Bioscience Holdings Limited has completed an IPO in the amount of $21.85 million.
CI
Regencell Bioscience Holdings Limited has filed an IPO in the amount of $17.724375 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGC Stock
  4. News Regencell Bioscience Holdings Limited
  5. Highlights